Yes, excellent news for us and a great example as to why nailing down our patents and Nina’s excellent deal making is the differentiator among Aussie biotechs.
The deal Fuso made with DXB is less than what the other drug company I posted about has to pay for infringing on a patent that had been extended.
Looking forward to all of the options being exercised (or expire) then next news flow and milestones.
DXB Price at posting:
58.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)